Outcomes of Drug Resistant Epileptic Pediatric Patient by Modified Atkins Diet
To assess clinical outcomes in drug resistant epileptic pediatric patient by modified atkin diet with focusing on following points:
- Control of seizures(frequency , duration and numbers of hospital admissions) .
- Quality of life by pediatric quality of life inventory v4.
- Cognitive function by stanford binet intelligence scale 5th edition.
- Growth parameters ( weight, height will be combined to report BMI in kg/m^2).
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Mahmoud Saber Elsayed
- Phone Number: 00201069770585
- Email: Mm.ss.elsayed277@gmail.com
Study Locations
-
-
-
Sohag, Egypt
- Sohag faculty of medicine
-
Contact:
- Sohag faculty of medicine
- Phone Number: 00201069770585
- Email: Mm.ss.elsayed227@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children aged 1-18 years.
- Diagnosed with drug-resistant epilepsy according to ILAE definition.[2]
- On KD for at least 6 months.
Exclusion Criteria:
- - Patients with contraindicated metabolic/genetic conditions.
- Non-compliance with KD .
Patients on alternative dietary therapies (e.g., low glycemic diet)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
1-Control of seizures(frequency and duration of seizures) . 2-Quality of life by pediatric quality of life inventory v4. 3-Cognitive function by stanford binet intelligence scale 5th edition. 4-Growth parameters (weight and height by BMI in kg/m^2)
Time Frame: 6 month
|
6 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
to detect clinical predictors of seizures control ( frequency of attack and duration) in patients with drug resistant epilepsy using MAD.
Time Frame: 6 month
|
6 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Soh-med-25-9-IMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.